Expression and characterization of Momordica Chanrantia anti-hyperglycaemic peptide in Escherichia coli
Related Experiment Video
Updated: Jun 21, 2026

Identification of Antibacterial Immunity Proteins in Escherichia coli using MALDI-TOF-TOF-MS/MS and Top-Down Proteomic Analysis
Published on: May 23, 2021
Si-Xiu Liu1, Zhong-Ping Fu, Rui-Min Mu
1Department of Environmental Science & Engineering, Urban Eco-Planning & Design Researching Center, Fudan University, 200433, Shanghai, People's Republic of China. liusixiu@gmail.com
Abstract:
A nucleic acid sequence MC, encoding Momordica Chanrantia anti-hyperglycaemic peptide MC6 (accession: AAX06814) synthesized according to Escherichia coli preferred codons, was cloned and expressed in E. coli. Recombinant protein pQE8-MC (about 3.5 kDa) was purified and analyzed by 20% SDS-PAGE and western blot. It revealed that the expressed pQE8-MC had good solubility in aqueous media. An HPLC assay was used to confirm the expression of pQE8-MC. Subsequent pharmacological activity assay revealed a significant hypoglycemic effect of low dose treatments of pQE8-MC on male kunming mice. Four hours after an intravenous tail injection, the blood sugar levels of mice treated with pQE8-MC saline solution A3 (1 mg/kg BW) decreased greatly (P < 0.01) relative to the levels of a control group. This suggests that pQE8-MC, expressed in bioengineered E. coli, has a similar hypoglycemic function to the natural protein MC6 from M. Chanrantia. These results reveal the possibility of using bio-engineered bacteria as an anti-diabetic agent.
Related Concept Videos
Stringent Response in E. coli
Bacterial Gastroenteritis
Production of Pharmaceuticals
